AUS
NZ
UK
CA
USA
IND
Iperionx Limited (ASX:IPX), specializing in critical minerals and advanced titanium technologies, has sought ASX approval for listing 106,093 fully paid ordinary shares following the exercise of unlisted options on 15 July 2026. These options, priced at AUD $0.87 each under the IPXAY series expiring 5 December 2026, have been fully exercised, leaving no remaining options in that series. This conversion raises Iperionx’s total quoted ordinary shares to 362,240,163, a development that critical minerals investors will likely monitor closely as the company progresses its titanium and rare earth initiatives.
Key Highlights
- Iperionx Limited (ASX:IPX) focuses on titanium and advanced materials within the critical minerals sector
- On 15 July 2026, 106,093 unlisted options (IPXAY series, expiring 5 December 2026, exercise price $0.87) were exercised and converted into fully paid ordinary shares
- Post-conversion, total quoted ordinary shares on issue stand at 362,240,163
- The IPXAY option series is now fully depleted with zero outstanding options
- Investors should monitor Iperionx’s remaining unquoted securities, including performance rights and options priced between $5.00 and $22.00, for potential future dilution
Impact of Exercising 106,093 IPXAY Options at $0.87 on Iperionx’s Share Register
On 15 July 2026, Iperionx Limited applied to the ASX to quote 106,093 new fully paid ordinary shares resulting from exercising options in the IPXAY series. These options, with an exercise price of AUD $0.87 each and originally set to expire on 5 December 2026, were exercised ahead of their expiry date. The shares were issued on the same day as the exercise, 15 July 2026, and will rank equally in all respects with existing ordinary shares.
The conversion was settled entirely in Australian dollars, with a cash consideration of $0.87 per option. Consequently, the gross proceeds from exercising all 106,093 options amounted to approximately $92,300. The company did not disclose net proceeds or fund usage details in the update. Following this conversion, the IPXAY series balance dropped to zero, confirming full exercise of all options in this class.
Iperionx’s Ordinary Shares Increase to 362,240,163 After July 2026 Conversion
After the quotation of the new shares, Iperionx’s total quoted fully paid ordinary shares reached 362,240,163, as recorded in Part 4 of the Appendix 2A filed with ASX on 15 July 2026. The filing notes that the issued capital figures may not reflect other simultaneous ASX processing activities, a standard administrative disclosure.
The addition of 106,093 shares represents less than 0.1% of the total share count, indicating minimal immediate dilution. However, investors should consider the broader capital structure, which includes numerous unquoted options and performance rights that could lead to future dilution. No immediate impact on share price was disclosed.
Complete Exhaustion of IPXAY Option Series Following Full Conversion
The IPXAY option class, expiring 5 December 2026 with an exercise price of $0.87, has been fully exercised as of 15 July 2026. This structural change removes one of the lower-strike-price option series from Iperionx’s register. Option holders have now become ordinary shareholders with full voting and economic rights. The company did not disclose whether the exercise involved a single or multiple holders.
Remaining Unquoted Securities Include Options Priced $5.00 to $22.00 and Multiple Performance Rights
Beyond the extinguished IPXAY series, Iperionx’s capital structure includes several unquoted securities as of 15 July 2026: IPXAB (511,972 options, $11.00 exercise price, expiring 2 April 2030), IPXAC (1,566,690 options, $18.00, expiring 2 April 2031), IPXAD (1,773,209 options, $22.00, expiring 2 April 2031), IPXAA (235,000 options, $10.00, expiring 1 April 2027), IPXAAC (1,305,000 options, $8.00, expiring 30 June 2027), and IPXAAD (1,374,746 options, $5.00, expiring 10 April 2029).
Additionally, multiple performance rights and restricted stock units remain outstanding, including IPXAE (660,077 rights, expiring 2 April 2031), IPXAAE (3,473,409 rights, expiring 10 April 2031), IPXAAA (2,440,000 rights, expiring 21 December 2028), IPXAAB (445,000 rights, expiring 31 December 2027), IPXAW (30,000 rights, expiring 31 December 2026), and IPXAP (4,110,668 restricted stock units). These securities could result in additional share issuance and potential dilution over time.
Structure and Early Exercise of Unlisted IPXAY Options
The converted IPXAY options were unlisted, privately held securities not traded on the ASX secondary market, typically issued through employee incentives, capital raising, or corporate arrangements. The Appendix 2A filing initiates the process for ASX quotation of the new shares.
The exercise on 15 July 2026, five months before the 5 December 2026 expiry, indicates a strategic decision by the holder(s) to convert early. The exercise price was fixed at grant, and payment was made in Australian dollars. No commentary was provided on the timing or parties involved.
Iperionx’s Titanium and Critical Minerals Focus Underpins Capital Movements
Iperionx operates in the critical minerals space with a focus on titanium and advanced materials, vital for aerospace, defense, medical, and industrial uses. The company is advancing lower-cost, lower-emission titanium metal production technologies amid growing investor and government interest driven by global supply chain concerns.
The company’s capital structure activities, including option exercises and management of performance rights, reflect its progression from exploration to production phases. This update is primarily administrative, with no operational or project developments disclosed.
Appendix 2A Filing Confirms New Shares’ Equal Ranking and Quotation
The Appendix 2A filing formally requests ASX quotation of the 106,093 new ordinary shares under the IPX code. The company confirmed these shares rank equally with existing ordinary shares in voting, dividends, and other rights, effective from the issue date of 15 July 2026. The exercise, issuance, and quotation application all occurred on the same day, consistent with standard procedures.
No additional commentary was provided beyond the standard filing information.
Risk Alert: Potential Dilution from Iperionx’s Extensive Unquoted Convertible Securities
Investors should be aware of potential dilution risks from Iperionx’s significant number of unquoted convertible securities. The largest unquoted classes include 3,473,409 performance rights (IPXAAE) and 4,110,668 restricted stock units (IPXAP). Full exercise or vesting of these could substantially increase shares outstanding beyond the current 362,240,163.
Not all securities will necessarily convert, as some options have high exercise prices relative to market value and performance rights depend on vesting conditions. Nonetheless, these instruments are critical factors when evaluating the company’s fully diluted share count and shareholder ownership dilution. No details on vesting or exercise likelihood were disclosed.
